These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 28886907

  • 1. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A.
    Lancet; 2017 Nov 11; 390(10108):2143-2159. PubMed ID: 28886907
    [Abstract] [Full Text] [Related]

  • 2. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
    Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A, Broad Spectrum HPV Vaccine Study.
    N Engl J Med; 2015 Feb 19; 372(8):711-23. PubMed ID: 25693011
    [Abstract] [Full Text] [Related]

  • 3. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
    Van Damme P, Meijer CJLM, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M.
    Vaccine; 2016 Jul 29; 34(35):4205-4212. PubMed ID: 27354258
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
    Ruiz-Sternberg ÁM, Moreira ED, Restrepo JA, Lazcano-Ponce E, Cabello R, Silva A, Andrade R, Revollo F, Uscanga S, Victoria A, Guevara AM, Luna J, Plata M, Dominguez CN, Fedrizzi E, Suarez E, Reina JC, Ellison MC, Moeller E, Ritter M, Shields C, Cashat M, Perez G, Luxembourg A.
    Papillomavirus Res; 2018 Jun 29; 5():63-74. PubMed ID: 29269325
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
    Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N, Joshi S, Pimple S, Kawade A, Balasubramani L, Thomas A, Suri V, Lalwani S, Uday R, Kamath V, Mandal R, Rajeswar A, Peedicayil A, Poli UR, Banerjee D, Sankaranarayanan R, Basu P, Muwonge R, Gairola S, Dogar V, Rao H, Shaligram U.
    Lancet Oncol; 2023 Dec 29; 24(12):1321-1333. PubMed ID: 37949086
    [Abstract] [Full Text] [Related]

  • 6. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M.
    Pediatr Infect Dis J; 2015 Sep 29; 34(9):992-8. PubMed ID: 26090572
    [Abstract] [Full Text] [Related]

  • 7. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
    Giuliano AR, Joura EA, Garland SM, Huh WK, Iversen OE, Kjaer SK, Ferenczy A, Kurman RJ, Ronnett BM, Stoler MH, Bautista OM, Moeller E, Ritter M, Shields C, Luxembourg A.
    Gynecol Oncol; 2019 Jul 29; 154(1):110-117. PubMed ID: 30982556
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N, Ansah NA, Marino D, Saah A, Garner EI.
    Hum Vaccin Immunother; 2015 Jul 29; 11(6):1323-30. PubMed ID: 25912475
    [Abstract] [Full Text] [Related]

  • 9. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, Riveros-Balta AX, Low N, Henschke N.
    Cochrane Database Syst Rev; 2019 Nov 22; 2019(11):. PubMed ID: 31755549
    [Abstract] [Full Text] [Related]

  • 10. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P, Tobe K, Abe M, Elbasha EH.
    BMC Infect Dis; 2021 Jan 06; 21(1):11. PubMed ID: 33407188
    [Abstract] [Full Text] [Related]

  • 11. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
    Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, Van Damme P, Moreira ED, Ferris D, Block S, Bautista O, Gallagher N, McCauley J, Luxembourg A.
    Papillomavirus Res; 2020 Dec 06; 10():100203. PubMed ID: 32659510
    [Abstract] [Full Text] [Related]

  • 12. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    FUTURE I/II Study GroupDepatment of Laboratory Medicine, Lund University, Malmö, Sweden. joakim.dillner@med.lu.se, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.
    BMJ; 2010 Jul 20; 341():c3493. PubMed ID: 20647284
    [Abstract] [Full Text] [Related]

  • 13. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A.
    Lancet; 2009 Jun 06; 373(9679):1949-57. PubMed ID: 19493565
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A.
    Vaccine; 2015 Nov 27; 33(48):6855-64. PubMed ID: 26411885
    [Abstract] [Full Text] [Related]

  • 15. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, Penny ME, Cabello RE, Moreira ED, Baraldi E, Jessen H, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Bautista O, Das R, Group T, Luxembourg A, Zhou HJ, Saah A.
    Lancet Infect Dis; 2022 Mar 27; 22(3):413-425. PubMed ID: 34780705
    [Abstract] [Full Text] [Related]

  • 16. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.
    Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI.
    N Engl J Med; 2011 Oct 27; 365(17):1576-85. PubMed ID: 22029979
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
    Garland SM, Anagani M, Bhatla N, Chatterjee S, Lalwani S, Ross C, Group T, Lin J, Luxembourg A, Walia A, Tu Y.
    Hum Vaccin Immunother; 2022 Nov 30; 18(6):2105067. PubMed ID: 35997582
    [Abstract] [Full Text] [Related]

  • 18. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
    Luxembourg A, Bautista O, Moeller E, Ritter M, Chen J.
    Contemp Clin Trials; 2015 May 30; 42():18-25. PubMed ID: 25749310
    [Abstract] [Full Text] [Related]

  • 19. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, HPV PATRICIA Study Group.
    Lancet Oncol; 2012 Jan 30; 13(1):89-99. PubMed ID: 22075171
    [Abstract] [Full Text] [Related]

  • 20. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
    Zhang Z, Zhang J, Xia N, Zhao Q.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2280-2291. PubMed ID: 28699820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.